GlassScriptPhysician profile
Angela M Cloud
NPI 1629615240
$1,243.19
in general payments reported to CMS, 2019-2025
21 companies · $604 in 2025
The $604 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $211 · 2024: $428 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $248.56 | 2023-2025 | Repatha, Repatha, Evenity |
| Edwards Lifesciences Corporation | $221.41 | 2023-2025 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $107.31 | 2025 | Veozah |
| Nevro Corp. | $89.26 | 2024 | Senza |
| Lilly USA, LLC | $63.99 | 2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $60.19 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $58.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $51.81 | 2023 | Arexvy |
| Eisai INC. | $47.83 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.24 | 2023-2024 | Xifaxan |
| Pfizer INC. | $33.14 | 2024 | |
| Lundbeck LLC | $32.09 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.47 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $26.80 | 2025 | |
| Spr Therapeutics, INC | $25.24 | 2025 | Sprint Pns System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.74 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $22.57 | 2025 | Zenpep |
| Neurelis, INC. | $20.02 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2024 | Trintellix |
| Ardelyx, INC. | $15.88 | 2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Cloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.